Part I. A ReviewThe Current Status of Tumor Targeting: A ReviewTarunendu GhoseClinical Applications of Targeted TherapeuticsTarunendu GhosePart II. Targeting Tumors with Drug Antibody ConjugatesTargeting the CD22 Receptor with RNA Damaging AgentsHuaitian Liu, Dianne L. Newton, Hans J. Hansen, Stanislaw M. Mikulski, David M. Goldenberg, Edward A. Sausville, and Susanna M. RybakThe Development of Liposomes for Enhanced Delivery of Chemotherapeutics to TumorsPaul Tardi, Ludger Ickenstein, Marcel Bally, and Lawrence MayerOvercoming Multiple Drug Resistance with Anti-Pgp CarrierBrigitte Pag? and Michel Pag?Targeting with Transferrin, Mandip SinghSynthesis and Evaluation of Paclitaxel Immunoconjugate with Antitumor Activity In VitroJairo Jaime Correa and Michel Pag?The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of CancerGeoffrey A. Pietersz and Ian F. C. McKenziePart III. Targeting Tumors with AntibodiesTargeting Vascular Endothelium with AntibodiesPrzemek Twardowski and Kim MargolinTargeting B-Cell Non-Hodgkin's Lymphoma with Monoclonal AntibodiesChristian Buske and W. HiddemannFrom Bench to Bedside: Development of Rituximab (Rituxan ?), A Monoclonal Antibody for the Therapy of Non-Hodgkin's LymphomaRoland NewmanMylotarg: The First Antibody-Targeted Chemotherapy AgentPhilip R. Hamann and Mark S. BergerPart IV. Targeting Tumors with Radioimmunoconjugates188Rhenium-Labeled Trisuccin-DCh2HuCC49 as a Radioimmunotherapy Model in Nude MiceAhmad Safavy and Donald J. BuchsbaumPart V. Targeting Tumors with ImmunotoxinsGeneral Approach for Targeting ToxinsManish Monga, Richard A. Messman, and Edward A. SausvilleAntibody-Toxin Conjugates: Chemistry of Couplingand PurificationSilvana Canevari, Maria Ines Colnaghi, Luigi Cattel, and Franco DosioShiga-Like Toxins as Targeted Anticancer AgentsPaul LaPointe and Jean Gari?pyPart VI. Targeting Tumors with Antibody-Enzyme Conjugates (ADEPT)Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical StudieslÃÕ